190 filings
Page 8 of 10
6-K
IMAB
I-Mab
17 Sep 20
Current report (foreign)
4:01pm
SC 13D
IMAB
I-Mab
14 Sep 20
I-Mab / HILLHOUSE CAPITAL ADVISORS ownership change
5:19pm
6-K
IMAB
I-Mab
4 Sep 20
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
7:03am
6-K
IMAB
I-Mab
4 Sep 20
Current report (foreign)
7:02am
6-K
IMAB
I-Mab
1 Sep 20
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update
6:10am
6-K
IMAB
I-Mab
18 Aug 20
I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China
6:06am
6-K
IMAB
I-Mab
5 Aug 20
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency
6:07am
6-K
IMAB
I-Mab
29 Jul 20
I-Mab Drives Commercialization Strategy with Appointment
6:13am
6-K
IMAB
I-Mab
15 Jul 20
I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million
4:51pm
S-8
IMAB
I-Mab
15 Jul 20
Registration of securities for employees
4:04pm
6-K
IMAB
I-Mab
15 Jun 20
I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific
6:15am
6-K
IMAB
I-Mab
28 May 20
I-Mab Reports Interim Results from Part 1 Study forAnti-GM-CSF Antibody TJM2 to Treat
6:22am
6-K
IMAB
I-Mab
21 May 20
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of
8:50am
6-K
IMAB
I-Mab
13 May 20
Current report (foreign)
4:01pm
20-F
2019 FY
IMAB
I-Mab
29 Apr 20
Annual report (foreign)
9:13am
6-K
IMAB
I-Mab
28 Apr 20
I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202
6:14am
6-K
IMAB
I-Mab
17 Apr 20
Current report (foreign)
4:01pm
6-K
IMAB
I-Mab
8 Apr 20
Current report (foreign)
6:29am
6-K
IMAB
I-Mab
6 Apr 20
Current report (foreign)
4:06pm
6-K
IMAB
I-Mab
2 Apr 20
Initiation of development of TJC4 in China follows an ongoing Phase 1 study in U.S. for advanced solid tumors and lymphoma
4:03pm